Skip to main content
Oculis Holding AG logo

Oculis Holding AG — Investor Relations & Filings

Ticker · OCS ISIN · CH1242303498 LEI · 5067005370C2KK324336 IC Manufacturing
Open in API
Filings indexed 321 across all filing types
Latest filing 2024-06-10 Regulatory Filings
Country CH Switzerland
Listing IC OCS

About Oculis Holding AG

https://www.oculis.com/

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings
2024-06-10 English
Oculis kynnir jákvæðar niðurstöður úr fasa 2b RELIEF-rannsókn með Licaminlimab, hannað til að umbylta meðferð augnþurrks með nákvæmnislyfjameðferð
Earnings Release Classification · 95% confidence The document is a press release from Oculis Holding AG announcing positive topline results from a Phase 2b clinical trial (RELIEF) for their drug candidate, Licaminlimab. It details the study's findings, clinical significance, and future plans for Phase 3 trials, while also inviting investors to a conference call. This fits the definition of an Earnings Release or a general corporate announcement regarding clinical trial results, which falls under the 'Earnings Release' (ER) category in this taxonomy as it is the primary announcement of periodic/event-based financial/operational highlights. Q2 2024
2024-06-10 Icelandic
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
Earnings Release Classification · 95% confidence The document is a press release from Oculis Holding AG announcing positive topline results from a Phase 2b clinical trial. It details the trial methodology, efficacy endpoints, safety data, and future development plans (End-of-Phase 2 meeting with the FDA). This type of announcement, which provides key highlights of clinical trial results to the public and investors, is classified as an Earnings Release (ER) or a general regulatory announcement. Given the specific focus on clinical trial results and the subsequent investor call, it fits best under the Earnings Release (ER) category as it serves as a periodic update on company performance and development milestones. Q2 2024
2024-06-10 English
Notification of managers transaction - Rosenberg - 2024 annual.pdf
Director's Dealing Classification · 100% confidence The document is a standard notification form for transactions by persons discharging managerial responsibilities (PDMRs), specifically detailing a grant of restricted stock units (RSUs) to a member of the Board of Directors (Anthony Rosenberg) of Oculis Holding AG. This type of disclosure is explicitly defined as a 'Director's Dealing' (DIRS) under the provided filing categories.
2024-06-04 English
Notification of managers transaction - Khanani - new director.pdf
Director's Dealing Classification · 100% confidence The document is a standard template for the notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMRs), specifically detailing a grant of restricted stock units to a member of the Board of Directors. This falls under the category of Director's Dealing (DIRS), which covers insider trades and transactions by company executives.
2024-06-04 English
Notification of managers transaction - Warner - new director.pdf
Director's Dealing Classification · 100% confidence The document is a standard template for the notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMRs). It identifies Robert Warner, a member of the Board of Directors, as the person involved in the transaction (grant of stock options). This type of filing is specifically categorized as a Director's Dealing (DIRS) under the provided definitions, as it reports personal share/option transactions by company directors.
2024-06-04 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.